Where to for global growth, tech & life sciences? | Michael Frazis
Murdoch speaks with Michael Frazis the MD & PM of Frazis Capital Partners about AI, Tech, Life Sciences & his new A.I. risk management tool.
Finding growth in global technology and life sciences | Michael Frazis
In today's ROCast Murdoch speaks with Michael Frazis, the founder and portfolio manager at Frazis Capital Partners.
Pharma and biotech - Checking in on IPOs
Sector Overview The IIR Pharma & Biotech Index increased 2.9% in the month of June, in line with the broader market with the ASX All Ordinaries Accumulation Index up...
For the love of growth: How Michael Frazis finds 100-baggers
It's highly likely that over the past 12 months you have become acquainted with fresh-faced portfolio manager Michael Frazis. After all, he has graced the pages of...
The key to capturing a 20-bagger
In our inaugural podcast for 2020, I sit down with Peter Stevens, Investment Analyst at Frazis Capital, to discuss the lessons we’ve taken to heart from last year and...
Actinogen Medical (ASX: ACW) - Breaking the long dry spell in Alzheimer’s treatment
Often in Life Sciences people speak of the 'Holy Grail' as something that everyone in a particular field is looking for and will be very pleased when it is found. It's...
Dimerix - the little Aussie company that is now a big player in Diabetic Nephropathy
I love it when ASX-listed Life Science companies generate pleasant surprises. For the last year or so we at NDF Research have been following Dimerix, a drug developer...
1-20 of 64